Key Points
- Insider sale: John Patrick Shannon, Jr. sold 24,907 shares on January 5 at an average price of $7.08 for proceeds of $176,341.56, leaving him with 2,705,346 shares (a 0.91% ownership decline, valued at about $19.15M).
- Stock and recent results: Xeris has a market cap of $1.15 billion, a negative P/E of -69.59 and a 1‑year range of $3.14–$10.08; it reported $0.00 EPS (missing the $0.01 estimate) and $74.38M revenue for the most recent quarter.
- Analyst view: The consensus is a "Moderate Buy" (six Buys, two Holds, one Sell) with an average price target of $9.50, though analysts have issued mixed ratings and recent downgrades alongside some overweight/outperform recommendations.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 24,907 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $7.08, for a total transaction of $176,341.56. Following the completion of the sale, the insider directly owned 2,705,346 shares in the company, valued at $19,153,849.68. This represents a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Xeris Biopharma Stock Performance
Xeris Biopharma stock opened at $6.96 on Wednesday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -69.59 and a beta of 0.50. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.14 and a 1 year high of $10.08. The firm has a 50 day moving average price of $7.48 and a 200 day moving average price of $7.14.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. Sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.
Institutional Investors Weigh In On Xeris Biopharma
Large investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers increased its stake in Xeris Biopharma by 3.9% during the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company's stock worth $216,000 after buying an additional 1,735 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Xeris Biopharma by 7.6% during the second quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company's stock worth $150,000 after acquiring an additional 2,264 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Xeris Biopharma by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company's stock worth $254,000 after acquiring an additional 3,562 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company's stock valued at $461,000 after purchasing an additional 3,594 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in Xeris Biopharma by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 691,381 shares of the company's stock valued at $3,229,000 after purchasing an additional 3,598 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research analysts recently commented on the stock. Zacks Research lowered shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, October 30th. Wall Street Zen downgraded shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Saturday, November 8th. Barclays initiated coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They set an "overweight" rating and a $9.00 target price on the stock. Oppenheimer reiterated an "outperform" rating and issued a $18.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, Piper Sandler boosted their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the stock a "neutral" rating in a research note on Friday, November 7th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $9.50.
Get Our Latest Report on XERS
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
